Who we are

AntiApp Technologies was founded on a simple but urgent truth: obesity is a chronic, progressive disease that drives many of today’s most serious health conditions — including type 2 diabetes, cardiovascular disease, and inflammatory disorders. Beyond its physical toll, obesity profoundly impacts quality of life, mental well-being, and long-term healthcare costs.

Despite increased awareness and new pharmacologic options, long-term weight management remains one of healthcare’s most complex challenges. Sustainable success requires more than willpower. It requires biology-driven solutions that support appetite regulation, metabolic health, and behavioral adherence.

That is where AntiApp Technologies comes in.

Our focus

AntiApp develops clinically informed functional and medical nutrition innovations designed to:

Enhance satiety
Support appetite regulation
Improve adherence to calorie control
Promote sustainable, healthy weight management

Our solutions are designed to work:

As a standalone nutritional strategy
In conjunction with physician-guided weight loss programs
As a transition or maintenance support following GLP-1 or other pharmacologic interventions

We recognize that medication alone is rarely a permanent solution. Long-term success depends on building sustainable biological and behavioral frameworks. AntiApp aims to fill the critical gap between pharmaceutical intervention and lasting lifestyle stability.

Our Philosophy

Obesity is not a failure of character. It is a complex metabolic condition influenced by appetite signaling, hormonal pathways, inflammation, and environmental factors.

Most individuals struggling with weight are battling dysregulated hunger cues and metabolic adaptation — not simply a lack of discipline. By focusing on satiety signaling and appetite biology, AntiApp is developing solutions that work with the body, not against it.

We believe the future of weight management will be:

Science-driven
Integrative
Personalized
Sustainable

And centered on long-term health, not short-term reduction.

Our Vision

To become a leader in next-generation functional and medical nutrition technologies that support weight management before, during, and after pharmaceutical intervention.

As the healthcare landscape evolves, particularly with the rise of GLP-1 therapies, the need for structured nutritional innovation has never been greater. AntiApp is positioned at the intersection of metabolic science, clinical need, and real-world adherence.

We are building solutions designed not just for weight loss, but for weight stability, metabolic resilience, and improved quality of life.

our founder

Dr. C.S. Rao (Dr. Sam Rao)

AntiApp Technologies was founded by Dr. C.S. Rao, known as Dr. Sam Rao, with a clear mission to address one of the most pressing drivers of chronic disease worldwide.

Recognizing that obesity is a complex metabolic condition rather than simply a lifestyle issue, Dr. Rao established AntiApp Technologies to focus on science-informed functional nutrition solutions that support appetite regulation and sustainable weight management.

His vision is to develop practical, biologically aligned tools that can work independently or alongside medical therapies to help individuals achieve long-term metabolic stability and improved quality of life.

Under his leadership, AntiApp Technologies is committed to innovation grounded in scientific rationale and real-world application, with a focus on lasting health outcomes.

Dr. Rao holds a Ph.D. in Biochemistry and Food Science in the United States and a Doctor of Veterinary Medicine degree from India. Throughout his career he has taught and worked across three continents including Asia, South America, and North America, gaining a global perspective on food science and nutrition while becoming proficient in several languages.

Most recently he served as Vice President of Research and Development and Innovation, where he led advancements in functional foods. A U.S. citizen, Dr. Rao founded AntiApp Technologies out of a deep personal passion to address obesity and metabolic health through science-driven solutions.

OUR ADVISORS

Dr. Jon A. Vanderhoof

Dr. Jon A. Vanderhoof is Chief of Pediatric Gastroenterology at Boys Town National Research Hospital in Omaha and an attending physician at Boston Children’s Hospital. He is also a Senior Lecturer at Harvard Medical School and Professor Emeritus of Pediatrics at the University of Nebraska College of Medicine.
Dr. Vanderhoof previously led Pediatric Gastroenterology and Nutrition at the University of Nebraska Medical Center for three decades and served as Chief Medical Officer for Mead Johnson Nutrition. A nationally recognized expert in pediatric gastroenterology and nutrition, he has authored nearly 200 scientific publications and received the prestigious Shwachman Award for lifetime contributions to the field.
Dr. Alekha K. Dash

Dr. Alekha K. Dash is a Professor in the Department of Pharmacy Sciences and holds the Gilbert S. Banker Endowed Chair in Pharmacy. He also serves as Associate Dean for Research. His work focuses on the design and evaluation of novel drug delivery systems, pharmaceutical analysis, and the development of dosage forms for drugs and nutraceuticals. Bio of Dr.Dash
Dr. Dash has authored more than 150 peer-reviewed publications, holds multiple patents, and serves on several editorial boards for scientific journals. He is a Fellow of both the American Association of Colleges of Pharmacy and the American Association of Pharmaceutical Scientists, reflecting his leadership and contributions to pharmaceutical research and innovation.
Dr. Kaustav Majumder

Dr. Kaustav Majumder is an Associate Professor in the Department of Food Science and Technology at the University of Nebraska–Lincoln. He earned his Ph.D. from the University of Alberta, where his research focused on food and cardiovascular health, and completed postdoctoral training at the University of Guelph specializing in food allergy and allergenic protein characterization.
Dr. Majumder leads the FoodBioPep Lab, which develops peptide-based functional foods aimed at preventing and managing cardiometabolic disorders. He has authored more than 50 peer-reviewed publications and contributed to multiple book chapters. His research has been recognized with several honors, including the Emerging Scientist Award at the Bioactive Peptide Symposium and Young Scientist Awards from the American Oil Chemists’ Society and the International Society of Nutraceuticals and Functional Foods.
Mr. Thomas L. Manuel

Thomas L. Manuel brings more than 45 years of leadership experience in the domestic and international food and agriculture industries. His career spans grain processing, meat and poultry production, commodity merchandising, and energy markets.
Mr. Manuel spent over 26 years with ConAgra Foods, where he served as President and Chief Operating Officer of ConAgra’s Trading and Processing Companies, a global network of independent operating businesses employing more than 40,000 people and generating more than $17 billion in annual sales.
After retiring from ConAgra in 2005, he co-founded Nu-Tek Food Science to develop innovative sodium-reduction technologies for processed foods. He later returned as CEO in 2011 to lead the commercialization of the company’s breakthrough sodium-reduction technology. During this period, he also served as CEO of two ethanol companies and held several corporate board positions.